Cargando…
COVID-19-Vaccine-Pfizer-BioNTech/ciclosporin/mycophenolate sodium: Vogt-Koyanagi-Harada disease reactivation and lack of efficacy: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446176/ http://dx.doi.org/10.1007/s40278-021-02508-6 |
Ejemplares similares
-
COVID-19 Vaccine Pfizer BioNTech: Vogt-Koyanagi-Harada disease exacerbation: case report
Publicado: (2022) -
COVID-19-Vaccine-Pfizer-BioNTech/mycophenolic acid/tacrolimus: Local reaction and lack of efficacy: 2 case reports
Publicado: (2021) -
Treatment of Vogt-Koyanagi-Harada Disease
por: Alaql, Musab K, et al.
Publicado: (2020) -
Tofacitinib in Vogt-Koyanagi-Harada disease
por: Dutta Majumder, Parthopratim, et al.
Publicado: (2020) -
An Unusual Presentation of Vogt–Koyanagi–Harada
por: Ipek, Sefik Can, et al.
Publicado: (2021)